Effect of atypical antipsychotics on blood glucose levels and HbA1c in patients of schizophrenia and bipolar disorder.

Abdul Hafeez Bughio¹, Shafak Jabeen Ansari², Rajesh Kumar³, Muhammad Hassan Sheikh⁴, Tarachand Devrajani⁵

ASTRACT... Objectives: To evaluate the effect of atypical antipsychotics on serum glucose levels and HbA1C in patients of schizophrenia and bipolar disorder. Study Design: Quasi-experimental study. Setting: Department of Neurology and Sir CJ Institute of Psychiatry LUMHS Jamshoro/Hyderabad. Period: Dec 2018-Dec 2019. Material & Methods: Total 360 participants of age more than 15 years of either gender presenting with psychiatric illness i.e. schizophrenia and bipolar disorder and prescribed same brand of antipsychotic drugs were included in the study. Fasting blood glucose (FBS), random blood glucose (RBS) and glycosylated hemoglobin (HbA1c) were measured at baseline and 6th months after treatment with atypical antipsychotic agents. SPSS version 23 was used to analyze data. Results: A total of 360 patients were enrolled in the study duration, among them 338 patients were followed up till 6 months, while 22 patients were lost to follow up. The mean age of the study sample was reported as 39.33±8.83 years. At baseline mean FBS, RBS and HbA1c were reported as 92.52±9 mg/dl, 143.21±14.91, 5.83±0.37 which significantly increase after treatment with antipsychotics at 6 months (p<0.05). About 23.6% developed diabetes mellitus and 21.3% developed hyperglycemia at the end of 6 months. Conclusion: Non-diabetic treatment naïve schizophrenia and bipolar disorders patients have higher chances developing side-effects on the glucose regulations after initiation of antipsychotic therapy. Overall, the early identification and diagnosis of antipsychotic-induced diabetes mellitus and hyperglycemia requires proper evaluation, reporting, and physician and patient awareness.

Key words: Atypical Antipsychotics, Bipolar Disorder, Diabetes Mellitus, Glucose Levels, Glycosylated Hemoglobin, Hyperglycemia, Schizophrenia.

INTRODUCTION

Antipsychotic drugs are treatments for symptoms of psychosis such as perceptual disturbance, delusions, disorganized behavior and the disorder of thought. Psychosis is prevalent in bipolar disorder and schizophrenia, as well as in dementia, major depressive disorder and few personality disorders.¹

In Pakistan recently there has been a rise in the use of antipsychotics, particularly atypical antipsychotics, with little polypharmacy. The overall use of antipsychotics increased by 4.3 fold in Pakistan. Olanzapine and risperidone were the most prescribed antipsychotics.² The use of atypical antipsychotics is associated with the severe disruption in whole blood glucose and lipid metabolism. This partially occurs through central nervous system and result in impaired insulin action through brain.³ Unfortunately, several studies have linked the patient on antipsychotic treatment with the occurrence of insulin resistance, impaired glucose tolerance and type 2 diabetes⁴,⁵ but the cause behind this correlation is not established. Research suggested that schizophrenia patients had higher diabetes levels than the normal population.⁶,⁷ It indicates that genetic or environmental factors may also be essential to psychiatric patients in increasing insulin resistance.⁸,⁹

Patients with schizophrenia are more likely than
the general population to develop diabetes, which contributes to a high risk of cardiovascular complications. Individuals with schizophrenia are two to three times more likely to die from cardiovascular disease than the general population.9,10 The risk of diabetes and hence cardiovascular disease is particularly increased by some of the new atypical antipsychotic drugs.11 Therefore, the aim of current study is to see the effect of atypical antipsychotics on HbA1c and serum glucose level of patients with schizophrenia and bipolar disorder.

MATERIAL & METHODS
It was a quasi-experimental study conducted at Sir C. J Institute of Psychiatry Hyderabad from Dec 2018-Dec 2019. Sample size was estimated using Open Epi sample size calculator by taking statistics for FBS (mg/dl) at baseline as 93.8 ± 2.12 and after use of antipsychotic at 6 months as 94.5 ± 1.77(12), power of test 90% and 95% confidence level. The estimated sample size was 328 patients, by inflating the sample size by 10% for loss to follow up total 360 patients were enrolled in the study. Patients of age more than 15 years of either gender presenting with psychiatric illness i.e. schizophrenia and bipolar disorder and prescribed same brand of antipsychotic drugs (either Olanzapine, Clozapine, Quetiapine or Risperidone) were included in the study using non-probability consecutive sampling technique. Patients with known history of cardiovascular events and diabetes, lactating and pregnant females, patients on medications which likely to interrelate with antipsychotic medicines were excluded from the study.

Ethical approval was sought out before conduct of study from institutional ethical review board. Written informed consent was obtained from legally effective person for all the eligible patients. Fasting blood glucose (FBS), random blood glucose (RBS) and glycosylated haemoglobin (HbA1c) were measured at baseline and 6th months after treatment with atypical antipsychotic agents, to check whether hyperglycaemia was drug induced or not. After 6 months, FBS greater than 100 mg/dl and RBS greater than 170 mg/dl was considered as hyperglycaemia positive whereas HbA1c more than more 6.5% were deemed as diabetes.

SPSS version 23 was used to enter and analyze data. Mean and SD were reported for all quantitative variables. Frequency and percentage were reported for all qualitative variables. Paired t-test was used to assess the mean difference in FBS, RBS and HbA1c level. Chi-square test was used to assess the association between different atypical antipsychotic drugs and hyperglycemia and diabetes mellitus. P<=0.05 was taken as statistically significant.

RESULTS
A total of 360 patients were enrolled in the study duration, among them 338 patients were followed up till 6 months, while 22 patients were lost to follow up. Therefore, analysis was carried out for 338 patients.

The mean age of the study sample was reported as 39.33±8.83 years ranging from 16 to 69 years. About 241 were males (71.3%) and 97 were females (28.7%). Out of 338 patients, 122 had positive family history of diabetes mellitus (36.1%).

At baseline mean FBS, RBS and HbA1c were reported as 92.52±9 mg/dl, 143.21±14.91, 5.83±0.37 which significantly increase after treatment with antipsychotics at 6 months by 6.2%, 7.6% and 4.2% respectively (p<0.05). The mean FBS, RBS and HbA1c were reported as 98.27±15.88 mg/dl, 154.12±28.20 and 6.08±0.74 at 6 months shown in Figure-1.

As compared to baseline, insignificant change was observed in FBS and RBS in quetiapine treated group at the end of 6th month (p>0.05), whereas HbA1c showed statistically significant increase at the end of 6th month (p<0.05). In clozapine, risperidone and olanzapine treated groups statistically significant changes were found in FBS, RBS and HbA1c at the end of 6th months as compared to baseline (p<0.05). (Table-I)

Almost half of the patients were treated with
risperidone (53%) followed by olanzapine (19.5%), quetiapine (13.9%) and clozapine (13.6%).

Overall 23.6% of the patients developed diabetes mellitus and among them patients who were treated with risperidone, 42.5% of the patients developed diabetes mellitus. There was statistically significant association between atypical antipsychotics and diabetes mellitus (p<0.05). (Table-II)

Overall 21.3% of the patients developed hyperglycemia and among them patients who were treated with risperidone, 38.9% of the patients developed hyperglycemia. There was statistically significant association between atypical antipsychotics and hyperglycemia (p<0.05). (Table-III)

| Parameters | Quetiapine | Clozapine | Risperidone | Olanzapine |
|------------|------------|-----------|-------------|------------|
| FBS (mg/dl) | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD |
| Baseline    | 94.62 ± 8.59 | 91.09 ± 7.42 | 92.88 ± 9.50 | 91.05 ± 8.66 |
| 6 months    | 91.74 ± 17.38 | 103.24 ± 12.00 | 97.54 ± 15.95 | 101.44 ± 15.38 |
| P-value     | 0.28 | 0.001 | 0.001 | 0.001 |

| RBS (mg/dl) | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD |
| Baseline    | 146.00 ± 13.22 | 145.17 ± 13.68 | 142.14 ± 15.96 | 142.77 ± 13.81 |
| 6 months    | 147.30 ± 19.64 | 163.65 ± 26.37 | 150.30 ± 26.75 | 162.68 ± 34.60 |
| P-value     | 0.61 | 0.001 | 0.001 | 0.001 |

| HbA1c (%) | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD |
| Baseline  | 5.81 ± 0.36 | 5.96 ± 0.32 | 5.82 ± 0.40 | 5.81 ± 0.33 |
| 6 months  | 5.91 ± 0.54 | 6.40 ± 0.79 | 5.98 ± 0.74 | 6.24 ± 0.78 |
| P-value   | 0.03 | 0.001 | 0.001 | 0.001 |

Table-I. Analysis of parameters in patients treated with different antipsychotics

| Atypical Antipsychotics | Diabetes Mellitus | Total | P-Value |
|-------------------------|-------------------|-------|---------|
| Yes                     | No                |       |         |
| Quetiapine              | 6(7.5%)           | 41(15.9%) | 47(13.9%) | 0.001 |
| Clozapine               | 17(21.3%)         | 29(11.2%) | 46(13.6%) |       |
| Risperidone             | 34(42.5%)         | 145(56.2%) | 179(53%) |       |
| Olanzapine              | 23(28.8%)         | 43(16.7%) | 66(19.5%) |       |

Table-II. Association between atypical antipsychotic drugs and diabetes mellitus

| Atypical antipsychotics | Hyperglycemia | Total | P-Value |
|-------------------------|---------------|-------|---------|
| Yes                     | No            |       |         |
| Quetiapine              | 5(6.9%)       | 42(15.8%) | 47(13.9%) | 0.003 |
| Clozapine               | 16(22.2%)     | 30(11.3%) | 46(13.6%) |       |
| Risperidone             | 28(38.9%)     | 151(56.8%) | 179(53%) |       |
| Olanzapine              | 23(31.9%)     | 43(16.2%) | 66(19.5%) |       |
DISCUSSION

The risk of developing diabetes mellitus increases for schizophrenia and bipolar disorder. The reasons are multifactorial, combining specific biological pathways, genetic susceptibility, ecological factors, and antipsychotics. In the current study we have evaluated the effect of antipsychotics on RBS, FBS and HbA1c levels of the patients with schizophrenia and bipolar disorder.

Patients seeking antipsychotic medication were diagnosed with elevated levels of blood glucose which increased over time. This finding is consistent with earlier studies that found that non-diabetic schizophrenic patients had adverse effects on glucose control after initiation of antipsychotic treatment, which can vary in severity independent of adiposity and potentially increase long-term cardiovascular risk. In the present study results showed statistically significant increase in FBS, RBS and HbA1c level after six months of treatment with antipsychotics (p<0.05). This finding support the fact that treatment naive bipolar and schizophrenia patients are at 2 to 3 times more risk of developing type 2 diabetes in adults as compared to healthy population. Another similar study showed that schizophrenia patients who were treated with various antipsychotics showed a continuous increase in fasting and post load plasma glucose levels on follow up. The mean FBS at baseline was 88.50 mg/dl which significantly increase as 102.93 mg/dl at the end of 14th week (p<0.05), whereas mean post load plasma glucose was 130.17 mg/dl at baseline which significantly increase as 153.02 mg/dl at the end of 14th week (p<0.05).

Quetiapine is an antipsychotic medication of second generation which is associated with the incidence of diabetes mellitus and hyperglycemia. Most of the hyperglycemia occurred within 3 months after initiation of treatment. It has also been noted that the risks of diabetes caused by the use of quetiapine varied insignificantly from that induced by conventional antipsychotics. In the present study, the patients treated with quetiapine showed decrease in FBS and RBS at the end of 6th month as compared to baseline, whereas HbA1c level increase at the end of 6th month. About 7.5% of the patients treated with quetiapine developed diabetes and 6.9% developed hyperglycemia at the end of 6 months. In a retrospective study, it has been found that 267 non-diabetic psychiatric patients who were treated with quetiapine 2.2% developed new-onset diabetes after 1.6 years.

Clozapine is an antipsychotic serotonin-dopamine antagonist (SDA) but in terms of binding to serotonin and dopamine receptors, efficacy and likelihood of side effects it varies from other SDA antipsychotics. Various studies have shown that there was a significantly higher incidence of metabolic syndrome among subjects taking clozapine than among subjects taking other antipsychotics. The impaired blood glucose level is an important parameter for the metabolic syndrome which leads to type II diabetes mellitus development. A study reported that over 1/3 of the participants were diagnosed with diabetes who were treated with clozapine after 5 years of follow-up therapy. The occurrence of clozapine-induced diabetes is generally thought to occur as part of a slowly evolving metabolic syndrome. Therefore, testing of fasting blood glucose is prescribed at baseline, after one-month treatment and then every 4 to 6 months during clozapine therapy. Several case reports identified an occurrence of hyperglycemia shortly after beginning clozapine with managed diabetes subjects. In the present study, 21.3% developed diabetes and 22.2% developed hyperglycemia after six months of treatment with clozapine. In a meta-analysis of 47 studies it has been found that associations of hyperglycemia and diabetes with clozapine were identified most commonly followed by olanzapine.

Olanzapine and risperidone shared the similar in vitro characteristics but they distinguish by virtue of their spectrum of receptor binding affinities, chemical structure, pharmacokinetics, neuropharmacology and in vivo neuroimaging profile. Few studies recommend that patients treated with olanzapine showed better response as compared to risperidone. In the present
study, the mean FBS level at baseline was 92.88 which significantly increase to 97.54 at the end of six months in patients treated with risperidone whereas in olanzapine group the mean FBS level was 91.05 at baseline which significantly increase to 101.44 at the end of six months. About 42.5% of the patients developed diabetes and 38.9% developed hyperglycemia in risperidone group whereas in olanzapine group 28.8% developed diabetes and 31.9% developed hyperglycemia at the end of six months. In a previous study it has been observed that mean FBS in risperidone versus olanzapine were 93.4 and 100.7 mg/mL at baseline, whereas at the end of 12th month the mean FBS in risperidone increased and in olanzapine decreased (108.9 vs 91.7), however there was insignificant changes was observed in FBS levels between the risperidone and olanzapine groups. Olanzapine is now commonly used as a first-line treatment for schizophrenia, providing efficacy that is equal to or better than other antipsychotic drugs, and has less extrapyramidal symptom, which is then a stigmatizing and sometimes incapacitating side effect for the patient. However, due to increasing evidence of hyperglycemic symptoms, as is also clear from our research, a prescription option now needs to be based.

Nonetheless, as is also apparent from our research, due to growing evidence of hyperglycemic consequences, a prescription option also needs to be focused on an evaluation of the potency of each medication as well as its potential to cause metabolic side effect. In fact, schizophrenia and bipolar disorder is a chronic disease requiring ongoing antipsychotic treatment, and an antipsychotic drug with less diabetes-related risk can be maintained to avoid psychotic regression and long-term degradation with least effect on glucose dysregulation.

CONCLUSION
Non-diabetic treatment naïve schizophrenia and bipolar disorders patients have higher chances developing side-effects on the glucose regulations after initiation of antipsychotic therapy. Overall, the early identification and diagnosis of antipsychotic-induced diabetes mellitus and hyperglycemia requires proper evaluation, reporting, and physician and patient awareness.

REFERENCES
1. Poa NR, Edgar PF. Insulin resistance is associated with hypercortisolism in Polynesian patients treated with antipsychotic medication. Diabetes Care. 2007; 30(6):1425-9.
2. Mahmood S, Hussain S, Ur Rehman T, Barbui C, Kurdi AB, Godman B. Trends in the prescribing of antipsychotic medicines in Pakistan: Implications for the future. Curr Med Res Opin. 2018:1-11.
3. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001; 62 Suppl 23:30-8.
4. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999; 40(5):438-43.
5. Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. MedGenMed. 2004; 6(1):5.
6. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: Another high-risk group for type 2 diabetes. Diabetes Care. 2003; 26(5):1597-605.
7. Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019; 19(10):96.
8. Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud. 2012; 9(1):6-22.
9. Dendup T, Feng X, Clingan S, Astell-Burt T. Environmental risk factors for developing type 2 diabetes mellitus: A systematic review. Int J Environ Res Public Health. 2018; 15(1).
10. Mangurian C, Newcomer JW, Modlin C, Schllinger D. Diabetes and cardiovascular care among people with severe mental illness: A literature review. J Gen Intern Med. 2016; 31(9):1083-91.
11. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009; 24(6):412-24.
12. Goswami NN, Gandhi AM, Patel PP, Dikshit RK. An evaluation of the metabolic effects of antipsychotic medications in patients suffering from psychiatric illness. Journal of Applied Pharmaceutical Science. 2014; 4(4):14.

13. Annamalai A, Tek C. An overview of diabetes management in schizophrenia patients: Office based strategies for primary care practitioners and endocrinologists. Int J Endocrinol. 2015; 2015:969182.

14. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002; 59(4):337-45.

15. Holt RI, Bushe C, Citrome L. Diabetes and schizophrenia 2005: Are we any closer to understanding the link? Journal of psychopharmacology (Oxford, England). 2005; 19(6 Suppl):56-65.

16. Wani RA, Dar MA, Margoob MA, Rather YH, Haq I, Shah MS. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment. J Neurosci Rural Pract. 2015; 6(1):17-22.

17. Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry. 2004; 65(6):857-63.

18. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS drugs. 2005;19 Suppl 1:1-93.

19. Lambert MT, Copeland LA, Sampson N, Duffy SA. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(5):919-23.

20. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004; 161(9):1709-11.

21. Rashid J, Starer PJ, Javed S. Pancreatitis and diabetic ketoacidosis with quetiapine use. Psychiatry (Edgmont (Pa : Township)). 2009;6(5):34-7.

22. Nanasawa H, Sako A, Mitsutsuka T, Nonogaki K, Kondo T, Mishima S, et al. Development of diabetes mellitus associated with quetiapine: A case series. Medicine (Baltimore). 2017; 96(3):e5900.

23. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res. 2009; 107(1):1-12.

24. Chadda RK, Ramshankar R Deb KS, Sood M. Metabolic syndrome in schizophrenia: Differences between atypical-naive and treated patients. J Pharmacol Pharmacother. 2013; 4(3):176-86.

25. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry. 2004; 37(1):1-11.

26. Henderson DC, Caglierio E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157(6):975-81.

27. Kar N, Barreto S, Chandavarkar R. Clozapine monitoring in clinical practice: Beyond the mandatory requirement. Clinical psychopharmacology and neuroscience: the official scientific journal of the Korean College of Neuropsychopharmacology. 2016;14(4):323-9.

28. Porras-Segovia A, Krivoy A, Horowitz M, Thomas G, Bolstridge M, Ion D, et al. Rapid-onset clozapine-induced loss of glycaemic control: case report. BJPsych open. 2017; 3(3):138-40.

29. Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: A network meta-analysis. BMC Psychiatry. 2017; 17(1):373.

30. Suresh Kumar PN, Anish PK, Rajmohan V. Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia. Indian J Psychiatry. 2016; 58(3):311-6.

31. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Jr., et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997; 17(5):407-18.

32. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27(2):596-601.
### AUTHORSHIP AND CONTRIBUTION DECLARATION

| Sr. # | Author(s) Full Name      | Contribution to the paper                                                                 | Author(s) Signature |
|-------|--------------------------|-------------------------------------------------------------------------------------------|---------------------|
| 1     | Abdul Hafeez Bughio      | Literature review and article writing.                                                    |                     |
| 2     | Shafak Jabeen Ansari     | Study design, Data collection and review.                                                  |                     |
| 3     | Rajesh Kumar             | Supervision of study.                                                                     |                     |
| 4     | M. Hassan Sheikh         | Data collection and literature review.                                                    |                     |
| 5     | Tarachand Devrajani      | Data collection and data review.                                                           |                     |